0      0

JL1114ES - JL1114ES: Impact of nirogacestat on functional status in patients with desmoid tumors: results from the phase 3 DeFi study

‐ Oct 27, 2023 4:00pm

Full author listing

Bernd Kasper, MD, PhD1, Mrinal M. Gounder, MD2, Ravin Ratan, MD, M.Ed3, Timothy Bell, MHA4, Shengfan Zhou4, Cristina Ivanescu, PhD5, James Marcus, PhD6, Allison Lim, PharmD4, Sandra Goble, MS4, Sunny Cho, PharmD4, Thierry Alcindor, MD, MSc7, Winette T. van der Graaf, MD, PhD8, Patrick Schöffski, MD, MPH9, Breelyn A. Wilky, MD10, Charlotte Benson, MBChB11, Nam Quoc Bui, MD12, Rashmi Chugh, MD13, Shivaani Kummar, MD14, Richard F. Riedel, MD15

1University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center, Sarcoma Unit, Mannheim, Germany; 2Sarcoma Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY, USA; 3Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4SpringWorks Therapeutics, Inc., Stamford, CT, USA; 5IQVIA, Patient Centered Solutions, Amsterdam, The Netherlands; 6IQVIA, Washington, DC, USA; 7Department of Oncology, McGill University, Montreal, QC, Canada; 8Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; 9Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium; 10Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA; 11The Royal Marsden NHS Foundation Trust, London, UK; 12Medicine – Oncology, Stanford Cancer Institute, Stanford, CA, USA; 13University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; 14Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; 15Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA


You must be logged in and own this session in order to post comments.